Is the Dream of Vascular Restoration Still Alive? A Case of 7 Years, Follow-Up After Bioresorbable Vascular Scaffold Implantation.
Bioresorbable scaffold (BRS)
Bioresorbable vascular scaffold (BVS)
Percutaneous coronary intervention
Journal
Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
10
2019
revised:
27
11
2019
accepted:
31
12
2019
pubmed:
8
2
2020
medline:
13
8
2021
entrez:
8
2
2020
Statut:
ppublish
Résumé
Bioresorbable scaffold (BRS) have the aim to combine short-term radial force by vessel scaffold (which should dissolve after few months), with drug eluting capability. It has been hypothesized that complete resorption would result in restoration of vasomotion, reduction in angina and reduction of restenosis. We report a case of 7 years angiographic follow up after DESolve Novolimus eluting Bioresorbable Coronary Scaffold System implantation. The invasive control showed persistence of scaffold patency and evidence of restored vascular motility by the growing in vessel diameter at QCA control after nitrates administration.
Sections du résumé
BACKGROUND
Bioresorbable scaffold (BRS) have the aim to combine short-term radial force by vessel scaffold (which should dissolve after few months), with drug eluting capability. It has been hypothesized that complete resorption would result in restoration of vasomotion, reduction in angina and reduction of restenosis.
CASE PRESENTATION
We report a case of 7 years angiographic follow up after DESolve Novolimus eluting Bioresorbable Coronary Scaffold System implantation.
CONCLUSION
The invasive control showed persistence of scaffold patency and evidence of restored vascular motility by the growing in vessel diameter at QCA control after nitrates administration.
Identifiants
pubmed: 32029391
pii: S1553-8389(20)30004-X
doi: 10.1016/j.carrev.2019.12.034
pii:
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
158-161Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Dr. Verheye has received speaker fees from Biotronik, Elixir Medical and Neovasc.